Takeda and Eli Lilly to pay a combined $9 billion in drug damages

Suit alleged the companies did not do enough to communicate potential cancer risk

A U.S. jury has determined that Takeda Pharmaceutical Co. and Eli Lilly & Co. conspired to hide cancer risks associated with the diabetes drug Actos. The drug makers will face a total of $9 billion in punitive damages as a result, with Takeda stock taking a heavy hit following the news.

The ruling came on April 8 and was the most recent in a series of decisions that required Takeda to pay punitive damages to patients.  Takeda is responsible for $6 billion of the damages, with its marketing partner Eli Lilly ordered to pay $3 billion.

Executive Editor

author image

Chris DiMarco

Chris DiMarco, Executive Editor of InsideCounsel magazine, has a background in multimedia production with previous involvement in projects in which he developed and created content...

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.